Published peptide research references
Taspoglutide
Governed registry record
4 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.
Approved source records
Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials.
Source identity and connection checked by Codex (AI).
Comparison of the efficacy and safety of GLP-1 receptor agonists on cardiovascular events and risk factors: A review and network meta-analysis.
Source identity and connection checked by Codex (AI).
Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trial.
Source identity and connection checked by Codex (AI).
Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes.
DOI: 10.1016/j.celrep.2021.109374
Source identity and connection checked by Codex (AI).
Legacy research context
Context from the legacy curated dataset. Its counts describe that dataset and are separate from the live approved source records above.
Researchers represented
- Zhang X
- Belousoff MJ
- Liang YL
- Danev R
- Sexton PM
- Wootten D
- Henry RR
- Mudaliar S
- Kanitra L
- Woloschak M
- Balena R
- T-Emerge 3 Study Group
- Seshasai SR
- Bennett RL
- Petrie JR
- Bengus M
- Ekman S
- Dixon M
- Herz M
- Buse JB
- Ray KK
- An X
- Sun W
- Wen Z
- Duan L
- Zhang Y
- Kang X
- Ji H
- Sun Y
- Jiang L
- Zhao X
- Gao Q
- Lian F